TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” 508 citations
,
June 2009 in “Current drug metabolism” Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
1 citations
,
May 2001 in “Pharmacology & Toxicology” Cyproterone acetate may cause liver cancer at high doses, but is considered safe at recommended doses for approved uses.
September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
Testosterone in our bodies helps increase insulin secretion from the pancreas.
5 citations
,
November 2012 in “Journal of Clinical Psychopharmacology” Valproic acid and isoniazid can interact, causing toxicity, so careful monitoring is needed.
November 2020 in “Universal Journal of Pharmaceutical Research” Tacrolimus is a better option than cyclosporine due to fewer side effects.
6 citations
,
October 2014 in “International Journal of Molecular Sciences” Tanshinone IIA helps protect tissue from low oxygen damage by activating certain cell pathways.
49 citations
,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
7 citations
,
April 2025 in “Science Advances” Silicate-based therapy may help treat inflammatory heart disease by reducing immune inflammation.
December 2023 in “Journal of Science Innovations and Nature of Earth” Tribulus terrestris may protect the liver from drug damage.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
4 citations
,
January 1998 in “Heterocycles” Researchers made two new compounds that could be used for medicine.
March 2026 in “Journal of the American Academy of Dermatology” The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.
3 citations
,
December 1994 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Oral itraconazole effectively reaches and treats deep skin layers in guinea pigs.
2 citations
,
January 2002 in “Dermatology + psychosomatics” Topiramate may cause reversible hair loss.
Testosterone in human pancreas cells boosts insulin production.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
April 2023 in “Journal of The American Academy of Dermatology” Some drugs linked to growth hormones may increase the chance of hair loss in women.
September 2019 in “Journal of Investigative Dermatology” Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
January 2008 in “Linchuang pifuke zazhi” Betamethasone activates and increases the growth of certain skin cells from hair follicles.
2 citations
,
February 2020 in “Rivista Urologia” Both terazosin and baclofen effectively reduce pain in young men with chronic testicular pain, with no difference in their effectiveness.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
68 citations
,
January 2013 in “BMC Pharmacology and Toxicology” Glibenclamide slows breast cancer cell growth by stopping cell division.